ImaLife
Imaging in Lifelines
Description
Lung cancer, chronic obstructive pulmonary disease (COPD), and coronary artery disease (CAD) are expected to cause most deaths by 2050. State-of-the-art computed tomography (CT) allows early detection of lung cancer and simultaneous evaluation of imaging biomarkers for the early stages of COPD, based on pulmonary density and bronchial wall thickness, and of CAD, based on the coronary artery calcium score (CACS), at low radiation dose. To determine cut-off values for positive tests for elevated risk and presence of disease is one of the major tasks before considering implementation of CT screening in a general population. The ImaLife (Imaging in Lifelines) study, embedded in the Lifelines study, is designed to establish the reference values of the imaging biomarkers for the big three diseases in a well-defined general population aged 45 years and older. In total, 12,000 participants will undergo CACS and chest acquisitions with latest CT technology. The estimated percentage of individuals with lung nodules needing further workup is around 1-2%. Given the around 10% prevalence of COPD and CAD in the general population, the expected number of COPD and CAD is around 1000 each. In the meantime, all participants have undergone CT scanning, and we are currently analyzing all scans. The ImaLife study will allow differentiation between normal aging of the pulmonary and cardiovascular system and early stages of the big three diseases based on low-dose CT imaging. This information can be finally integrated into personalized precision health strategies in the general population.
General Design
- Type
- Cohort study
- Cohort type
- Population cohort
- Data collection type
- Prospective
- Design
- Longitudinal
- Design schematic
- Design schematic
- Start/End data collection
- 2016 until 2025
- Design paper
- Early imaging biomarkers of lung cancer
- PID
- https://doi.org/10.34760/652667e86cd98
Population
- Countries
- Netherlands (the)
- Regions
- Drenthe, Friesland, Groningen
- Number of participants
- 12000
- Number of participants with samples
- 12000
- Population age groups
- Middle-aged (45-64 years), Aged (65+ years)
- Other inclusion criteria
- Completed second round Lifelines visit including lung function test
Organisations
Lead organisations
- University Medical Center Groningen (UMCG)Netherlands (the)https://www.umcg.nl
Additional organisations
- Siemens (Netherlands)Netherlands (the)https://new.siemens.com/
Contributors
- Rozemarijn VliegenthartUniversity Medical Center Groningenr.vliegenthart@umcg.nl
Principal Investigator, Primary contact
Available Data & Samples
Data categories
- Biological samples
- Imaging data
Subpopulations
List of subpopulations for this resource
| Name | Description | Number of participants | |
|---|---|---|---|
No results for current selection |
Collection events
List of collection events defined for this resource
| Name | Description | Participants | Start end year | |
|---|---|---|---|---|
No results for current selection |
Publications
Access conditions
Data access application via Lifelines and the PI
- Data use conditions
- collaboration required
- Release type
- Periodically
- Linkage options
- Linkages via Lifelines
Funding & Acknowledgements
- Funding
- The ImaLife study is supported by an institutional research grant from Siemens Healthineers and by the Ministry of Economic Afairs and Climate Policy by means of the PPP Allowance made avail?able by the Top Sector Life Sciences & Health to stimulate public private partnership.
- Acknowledgements
- We would like to thank all participants and technicians of the ImaLife study and also the Lifelines personnel.